{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:57:56Z","timestamp":1793127476943,"version":"4.5.0"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurochemistry International"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.neuint.2024.105774","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T12:18:52Z","timestamp":1716553132000},"page":"105774","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Molecular mechanisms of the ambroxol action in Gaucher disease and GBA1 mutation-associated Parkinson disease"],"prefix":"10.1016","volume":"178","author":[{"given":"Zuzanna","family":"Cyske","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Gaffke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estera","family":"Rintz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Wi\u015bniewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"W\u0119grzyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Pierzynowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.neuint.2024.105774_bib1","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/mds.20527","article-title":"A systematic review of prevalence studies of dementia in Parkinson's disease","volume":"20","author":"Aarsland","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuint.2024.105774_bib2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.nbd.2015.06.008","article-title":"Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells","volume":"82","author":"Ambrosi","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuint.2024.105774_bib3","article-title":"Promising effect of high dose ambroxol treatment on neurocognition and motor development in a patient with neuropathic gaucher disease 2","volume":"13","author":"Aries","year":"2020","journal-title":"Front. Neurol."},{"issue":"3","key":"10.1016\/j.neuint.2024.105774_bib4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ymgme.2012.04.018","article-title":"Pharmacological chaperones facilitate the post-ER transport of recombinant N370S mutant \u03b2-glucocerebrosidase in plant cells: evidence that N370S is a folding mutant","volume":"106","author":"Babajani","year":"2012","journal-title":"Mol. Genet. Metabol."},{"issue":"5","key":"10.1016\/j.neuint.2024.105774_bib5","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1177\/1073858417748875","article-title":"Glucocerebrosidase and Parkinson disease: molecular, clinical, and therapeutic implications","volume":"24","author":"Balestrino","year":"2018","journal-title":"Neuroscientist"},{"key":"10.1016\/j.neuint.2024.105774_bib6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.neuint.2015.12.004","article-title":"Advances in GBA-associated Parkinson's disease--Pathology, presentation and therapies","volume":"93","author":"Barkhuizen","year":"2016","journal-title":"Neurochem. Int."},{"issue":"2","key":"10.1016\/j.neuint.2024.105774_bib7","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jamaneurol.2014.2950","article-title":"Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort","volume":"72","author":"Beavan","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuint.2024.105774_bib8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejim.2016.07.011","article-title":"Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe","volume":"37","author":"Belmatoug","year":"2017","journal-title":"Eur. J. Intern. Med."},{"issue":"1","key":"10.1016\/j.neuint.2024.105774_bib9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bcmd.2010.10.012","article-title":"Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant","volume":"46","author":"Bendikov-Bar","year":"2011","journal-title":"Blood Cell Mol. Dis."},{"issue":"2","key":"10.1016\/j.neuint.2024.105774_bib10","first-page":"141","article-title":"Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase, Blood cells, molecules &amp","volume":"50","author":"Bendikov-Bar","year":"2013","journal-title":"Diseases"},{"issue":"3","key":"10.1016\/j.neuint.2024.105774_bib11","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/mds.26071","article-title":"GBA-associated Parkinson's disease: reduced survival and more rapid progression in a prospective longitudinal study","volume":"30","author":"Brockmann","year":"2015","journal-title":"Mov. Disord.: Off. J. Mov. Disord. Soc."},{"issue":"15","key":"10.1016\/j.neuint.2024.105774_bib12","doi-asserted-by":"crossref","first-page":"6857","DOI":"10.1021\/jm3006178","article-title":"Conformationally-locked N-glycosides with selective \u03b2-glucosidase inhibitory activity: identification of a new non-iminosugar-type pharmacological chaperone for Gaucher disease","volume":"55","author":"Castilla","year":"2012","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.neuint.2024.105774_bib13","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1080\/14740338.2018.1533954","article-title":"Safety of ambroxol in the treatment of airway diseases in adult patients","volume":"17","author":"Cazan","year":"2018","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.neuint.2024.105774_bib14","article-title":"Effect of Ambroxol chaperone therapy on Glucosylsphingosine (Lyso-Gb1) levels in two Canadian patients with type 3 Gaucher disease","volume":"20","author":"Charkhand","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"3","key":"10.1016\/j.neuint.2024.105774_bib15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1399-0004.2007.00769.x","article-title":"The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease","volume":"71","author":"Charrow","year":"2007","journal-title":"Clin. Genet."},{"issue":"9","key":"10.1016\/j.neuint.2024.105774_bib16","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01019-18","article-title":"Ambroxol induces autophagy and potentiates rifampin antimycobacterial activity","volume":"62","author":"Choi","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.neuint.2024.105774_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcmd.2019.102402","article-title":"Early initiation of high-dose oral ambroxol in combination with enzyme replacement therapy in a neuropathic Gaucher infant","volume":"81","author":"Chu","year":"2020","journal-title":"Blood Cell Mol. Dis."},{"key":"10.1016\/j.neuint.2024.105774_bib18","article-title":"In vitro and in vivo effects of Ambroxol chaperone therapy in two Italian patients affected by neuronopathic Gaucher disease and epilepsy","volume":"25","author":"Ciana","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"5","key":"10.1016\/j.neuint.2024.105774_bib19","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/ana.24777","article-title":"Survival and dementia in GBA-associated Parkinson's disease: the mutation matters","volume":"80","author":"Cilia","year":"2016","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.neuint.2024.105774_bib20","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1023\/A:1008814105603","article-title":"The health-related quality of life of adults with Gaucher's disease receiving enzyme replacement therapy: results from a retrospective study","volume":"7","author":"Damiano","year":"1998","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.neuint.2024.105774_bib21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.parkreldis.2021.08.010","article-title":"Pediatric Gaucher disease with intermediate type 2-3 phenotype associated with parkinsonian features and levodopa responsiveness","volume":"91","author":"Darling","year":"2021","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neuint.2024.105774_bib22","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF00441578","article-title":"Gaucher disease-norrbottnian type","volume":"133","author":"Dreborg","year":"1980","journal-title":"Eur. J. Pediatr."},{"issue":"6","key":"10.1016\/j.neuint.2024.105774_bib23","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.ceca.2015.10.002","article-title":"A new role for an old drug: ambroxol triggers lysosomal exocytosis via pH-dependent Ca2\u207a release from acidic Ca2\u207a stores","volume":"58","author":"Fois","year":"2015","journal-title":"Cell Calcium"},{"key":"10.1016\/j.neuint.2024.105774_bib24","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00702-023-02612-x","article-title":"Genetic testing for Parkinson's disease in clinical practice","volume":"130","author":"Gasser","year":"2023","journal-title":"J. Neural. Transm."},{"issue":"1","key":"10.1016\/j.neuint.2024.105774_bib25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13023-023-02623-7","article-title":"Glucosylsphingosine (Lyso-Gb1) as a reliable biomarker in Gaucher disease: a narrative review","volume":"18","author":"Giuffrida","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"issue":"2","key":"10.1016\/j.neuint.2024.105774_bib26","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.bcmd.2012.09.007","article-title":"Commentary on \"Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease\" by Zimran et al","volume":"50","author":"Goker-Alpan","year":"2013","journal-title":"Blood Cell Mol. Dis."},{"issue":"9645","key":"10.1016\/j.neuint.2024.105774_bib27","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","article-title":"Phenotype, diagnosis, and treatment of Gaucher's disease","volume":"372","author":"Grabowski","year":"2008","journal-title":"Lancet (London, England)"},{"issue":"8","key":"10.1016\/j.neuint.2024.105774_bib28","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3389\/fcell.2020.00271","article-title":"Small molecule chaperones for the treatment of gaucher disease and GBA1-associated Parkinson disease","volume":"19","author":"Han","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.neuint.2024.105774_bib29","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2147\/IJN.S229576","article-title":"Pulmonary-affinity paclitaxel polymer micelles in response to biological functions of ambroxol enhance therapeutic effect on lung cancer","volume":"15","author":"He","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.neuint.2024.105774_bib30","first-page":"117","article-title":"Combined beta-glucosylceramide and ambroxol hydrochloride in patients with Gaucher related Parkinson disease: from clinical observations to drug development. Blood cells","volume":"68","author":"Ishay","year":"2018","journal-title":"Mol. Dis."},{"issue":"5","key":"10.1016\/j.neuint.2024.105774_bib31","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/ajh.26131","article-title":"Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: investigator initiated registry based on real life data","volume":"96","author":"Istaiti","year":"2021","journal-title":"Am. J. Hematol."},{"issue":"7","key":"10.1016\/j.neuint.2024.105774_bib32","doi-asserted-by":"crossref","first-page":"6732","DOI":"10.3390\/ijms24076732","article-title":"High-dose ambroxol therapy in type 1 gaucher disease focusing on patients with poor response to enzyme replacement therapy or substrate reduction therapy","volume":"24","author":"Istaiti","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.neuint.2024.105774_bib33","first-page":"3750","article-title":"Individualized screening for chaperone activity in Gaucher disease using multiple patient derived primary cell lines","volume":"10","author":"Ivanova","year":"2018","journal-title":"Am. J. Tourism Res."},{"issue":"10","key":"10.1016\/j.neuint.2024.105774_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247211","article-title":"Cellular and biochemical response to chaperone versus substrate reduction therapies in neuropathic Gaucher disease","volume":"16","author":"Ivanova","year":"2021","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.neuint.2024.105774_bib35","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s10038-019-0704-3","article-title":"Ambroxol improves skeletal and hematological manifestations on a child with Gaucher disease","volume":"65","author":"Jiang","year":"2020","journal-title":"J. Hum. Genet."},{"issue":"9996","key":"10.1016\/j.neuint.2024.105774_bib36","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson's disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet (London, England)"},{"issue":"10","key":"10.1016\/j.neuint.2024.105774_bib37","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00256-014-1891-9","article-title":"Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat","volume":"43","author":"Kamath","year":"2014","journal-title":"Skeletal Radiol."},{"issue":"1","key":"10.1016\/j.neuint.2024.105774_bib38","first-page":"511","article-title":"An overview of efficacy and safety of ambroxol for the treatment of acute and chronic respiratory diseases with a special regard to children","volume":"15","author":"Kantar","year":"2020","journal-title":"Multidiscip. Respir. Med."},{"key":"10.1016\/j.neuint.2024.105774_bib39","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.3390\/biom13081227","article-title":"Therapeutic role of pharmacological chaperones in lysosomal storage disorders: a review of the evidence and informed approach to reclassification","volume":"13","author":"Keyzor","year":"2023","journal-title":"Biomolecules"},{"issue":"2","key":"10.1016\/j.neuint.2024.105774_bib40","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/jmedgenet-2019-106132","article-title":"Pharmacologic properties of high-dose ambroxol in four patients with Gaucher disease and myoclonic epilepsy","volume":"57","author":"Kim","year":"2020","journal-title":"J. Med. Genet."},{"issue":"1","key":"10.1016\/j.neuint.2024.105774_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15548627.2020.1797280","article-title":"Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1","volume":"17","author":"Klionsky","year":"2021","journal-title":"Autophagy"},{"key":"10.1016\/j.neuint.2024.105774_bib42","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.parkreldis.2021.02.003","article-title":"Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism","volume":"84","author":"Kopytova","year":"2021","journal-title":"Park. Relat. Disord."},{"issue":"4","key":"10.1016\/j.neuint.2024.105774_bib43","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.braindev.2012.05.008","article-title":"The chaperone activity and toxicity of ambroxol on Gaucher cells and normal mice","volume":"35","author":"Luan","year":"2013","journal-title":"Brain Dev."},{"issue":"3","key":"10.1016\/j.neuint.2024.105774_bib44","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/mt.2014.224","article-title":"Enzyme enhancers for the treatment of Fabry and Pompe disease","volume":"23","author":"Lukas","year":"2015","journal-title":"Mol. Ther. : J. Am. Soc. Gene Ther."},{"issue":"3","key":"10.1016\/j.neuint.2024.105774_bib45","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.achaem.2013.07.019","article-title":"What hematologist needs to know about Gaucher disease","volume":"44","author":"Machaczka","year":"2013","journal-title":"Acta Haematol. Pol."},{"issue":"35","key":"10.1016\/j.neuint.2024.105774_bib46","doi-asserted-by":"crossref","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","article-title":"Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease","volume":"284","author":"Maegawa","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuint.2024.105774_bib47","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/s41598-018-19479-8","article-title":"Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons","volume":"8","author":"Magalhaes","year":"2018","journal-title":"Sci. Rep."},{"issue":"13","key":"10.1016\/j.neuint.2024.105774_bib48","first-page":"2712","article-title":"The contribution of mutant GBA to the development of Parkinson disease in Drosophila","volume":"25","author":"Maor","year":"2016","journal-title":"Hum. Mol. Genet."},{"issue":"1","key":"10.1016\/j.neuint.2024.105774_bib49","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","article-title":"Gaucher disease glucocerebrosidase and \u03b1-synuclein form a bidirectional pathogenic loop in synucleinopathies","volume":"146","author":"Mazzulli","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.neuint.2024.105774_bib50","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/brain\/awu020","article-title":"Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells","volume":"137","author":"McNeill","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.neuint.2024.105774_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108419","article-title":"Targeting the GBA1 pathway to slow Parkinson disease: insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues","volume":"246","author":"Menozzi","year":"2023","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.neuint.2024.105774_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108419","article-title":"Targeting the GBA1 pathway to slow Parkinson disease: insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues","volume":"246","author":"Menozzi","year":"2023","journal-title":"Pharmacol. Therapeut."},{"issue":"5","key":"10.1016\/j.neuint.2024.105774_bib53","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/ana.24790","article-title":"Ambroxol effects in glucocerebrosidase and \u03b1-synuclein transgenic mice","volume":"80","author":"Migdalska-Richards","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuint.2024.105774_bib54","article-title":"Doustny ambroksol zwi\u0119ksza aktywno\u015b\u0107 glukocerebrozydazy w m\u00f3zgu u naczelnych innych ni\u017c cz\u0142owiek","volume":"71","author":"Migdalska-Richards","year":"2017","journal-title":"Synapsa"},{"issue":"1","key":"10.1016\/j.neuint.2024.105774_bib55","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.braindev.2005.04.005","article-title":"TB. De villemeur, French type 2 gaucher disease study group type 2 gaucher disease: 15 new cases and review of the literature","volume":"28","author":"Mignot","year":"2006","journal-title":"Brain Dev."},{"issue":"448","key":"10.1016\/j.neuint.2024.105774_bib56","article-title":"Pharmaceutical chaperones and proteostasis regulators in the therapy of lysosomal storage disorders: current perspective and future promises","volume":"8","author":"Mohamed","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.neuint.2024.105774_bib57","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jamaneurol.2019.4611","article-title":"Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial","volume":"77","author":"Mullin","year":"2020","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.neuint.2024.105774_bib58","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/acn3.292","article-title":"Ambroxol chaperone therapy for neuronopathic Gaucher disease: a pilot study","volume":"3","author":"Narita","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"Pt 7","key":"10.1016\/j.neuint.2024.105774_bib59","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1093\/brain\/awp044","article-title":"Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease","volume":"132","author":"Neumann","year":"2009","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.neuint.2024.105774_bib60","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.revmed.2018.11.012","article-title":"La maladie de Gaucher : quand y penser ? [Gaucher disease: A review]","volume":"40","author":"Nguyen","year":"2019","journal-title":"Rev. Med. Interne"},{"issue":"3","key":"10.1016\/j.neuint.2024.105774_bib61","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3233\/JPD-171092","article-title":"Glucocerebrosidase mutations in Parkinson disease","volume":"7","author":"O'Regan","year":"2017","journal-title":"J. Parkinsons Dis."},{"issue":"9","key":"10.1016\/j.neuint.2024.105774_bib62","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/stem.1732","article-title":"Gaucher iPSC-derived macrophages produce elevated levels of inflammatory mediators and serve as a new platform for therapeutic development","volume":"32","author":"Panicker","year":"2014","journal-title":"Stem Cell."},{"issue":"7","key":"10.1016\/j.neuint.2024.105774_bib63","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.3390\/ijms23073536","article-title":"Mechanistic insight into the mode of action of acid \u03b2-glucosidase enhancer ambroxol","volume":"23","author":"Pantoom","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuint.2024.105774_bib64","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.bcmd.2016.12.001","article-title":"The additive effect on the antiepileptic treatment of ambroxol in type 3 Gaucher patient. The early observation","volume":"68","author":"Pawlinski","year":"2018","journal-title":"Blood Cell Mol. Dis."},{"key":"10.1016\/j.neuint.2024.105774_bib65","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejpn.2021.03.013","article-title":"Early initiation of ambroxol treatment diminishes neurological manifestations of type 3 Gaucher disease: a long-term outcome of two siblings","volume":"32","author":"Ramad\u017ea","year":"2020","journal-title":"Eur. J. Paediatr. Neurol. : Off. J. Eur. Paediatr. Neurol. Soc."},{"issue":"15","key":"10.1016\/j.neuint.2024.105774_bib66","doi-asserted-by":"crossref","first-page":"e2119","DOI":"10.1212\/WNL.0000000000010605","article-title":"The natural history of type 2 Gaucher disease in the 21st century: a retrospective study","volume":"95","author":"Roshan Lal","year":"2020","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.neuint.2024.105774_bib67","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1080\/14656566.2021.1902989","article-title":"Current and emerging pharmacotherapy for Gaucher disease in pediatric populations","volume":"22","author":"Sam","year":"2022","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.neuint.2024.105774_bib68","doi-asserted-by":"crossref","DOI":"10.1038\/srep31380","article-title":"Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models","volume":"6","author":"Sanchez-Martinez","year":"2016","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.neuint.2024.105774_bib69","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1073\/pnas.1220464110","article-title":"Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies","volume":"110","author":"Sardi","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"10","key":"10.1016\/j.neuint.2024.105774_bib70","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1073\/pnas.1616152114","article-title":"Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models","volume":"114","author":"Sardi","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"3","key":"10.1016\/j.neuint.2024.105774_bib71","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/mds.24045","article-title":"Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course","volume":"27","author":"Set\u00f3-Salvia","year":"2012","journal-title":"Mov. Disord. : Off. J. Mov. Disord. Soc."},{"issue":"7","key":"10.1016\/j.neuint.2024.105774_bib72","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1194\/jlr.R047167","article-title":"The development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseases","volume":"55","author":"Shayman","year":"2014","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.neuint.2024.105774_bib73","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1750-1172-7-77","article-title":"The French Gaucher's disease registry: clinical characteristics, complications and treatment of 562 patients","volume":"7","author":"Stirnemann","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"issue":"2","key":"10.1016\/j.neuint.2024.105774_bib74","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3390\/ijms18020441","article-title":"A review of gaucher disease pathophysiology, clinical presentation and treatments","volume":"18","author":"Stirnemann","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuint.2024.105774_bib75","series-title":"Parkinson's Disease: Pathogenesis and Clinical Aspects","article-title":"Pathological mechanisms and clinical aspects of GBA1 mutation-associated Parkinson's disease","author":"Stoker","year":"2018"},{"issue":"6","key":"10.1016\/j.neuint.2024.105774_bib76","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.braindev.2012.12.002","article-title":"Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher disease","volume":"35","author":"Suzuki","year":"2013","journal-title":"Brain Dev."},{"issue":"8","key":"10.1016\/j.neuint.2024.105774_bib77","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069147","article-title":"Expression of human Gaucher disease gene GBA generates neurodevelopmental defects and ER stress in Drosophila eye","volume":"8","author":"Suzuki","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.neuint.2024.105774_bib78","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/15548627.2016.1247143","article-title":"Autophagy impairment with lysosomal and mitochondrial dysfunction is an important characteristic of oxidative stress-induced senescence","volume":"13","author":"Tai","year":"2017","journal-title":"Autophagy"},{"key":"10.1016\/j.neuint.2024.105774_bib79","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/bs.apcsb.2018.10.002","article-title":"A comparative computational approach toward pharmacological chaperones (NN-DNJ and ambroxol) on N370S and L444P mutations causing Gaucher's disease","volume":"114","author":"Thirumal Kumar","year":"2019","journal-title":"Adv. Protein Chem. Struct. Biol."},{"issue":"2","key":"10.1016\/j.neuint.2024.105774_bib80","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ymgme.2014.11.008","article-title":"The clinical management of Type 2 Gaucher disease","volume":"114","author":"Weiss","year":"2015","journal-title":"Mol. Genet. Metabol."},{"issue":"1","key":"10.1016\/j.neuint.2024.105774_bib81","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1359\/jbmr.061004","article-title":"Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease","volume":"22","author":"Wenstrup","year":"2007","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.neuint.2024.105774_bib82","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.stemcr.2017.01.011","article-title":"A human neural crest stem cell-derived dopaminergic neuronal model recapitulates biochemical abnormalities in GBA1 mutation carriers","volume":"8","author":"Yang","year":"2017","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.neuint.2024.105774_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104620","article-title":"Glucocerebrosidase activity, cathepsin D and monomeric \u03b1-synuclein interactions in a stem cell derived neuronal model of a PD associated GBA1 mutation","volume":"134","author":"Yang","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuint.2024.105774_bib84","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/mds.28815","article-title":"Evaluation of strategies for measuring lysosomal glucocerebrosidase activity","volume":"36","author":"Ysselstein","year":"2021","journal-title":"Mov. Disord."},{"issue":"12","key":"10.1016\/j.neuint.2024.105774_bib85","first-page":"2406","article-title":"Ambroxol enhances anti-cancer effect of microtubule-stabilizing drug to lung carcinoma through blocking autophagic flux in lysosome-dependent way","volume":"7","author":"Zhang","year":"2017","journal-title":"Am. J. Cancer Res."},{"issue":"6","key":"10.1016\/j.neuint.2024.105774_bib86","doi-asserted-by":"crossref","first-page":"658","DOI":"10.2174\/1871530321666211119145230","article-title":"Ambroxol chaperone therapy for gaucher disease type I-associated liver cirrhosis and portal hypertension: a case report","volume":"22","author":"Zhang","year":"2020","journal-title":"Endocr. Metab. Immune Disord. - Drug Targets"},{"issue":"2","key":"10.1016\/j.neuint.2024.105774_bib87","first-page":"134","article-title":"Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease. Blood cells","volume":"50","author":"Zimran","year":"2013","journal-title":"Mol. Dis."},{"issue":"1","key":"10.1016\/j.neuint.2024.105774_bib88","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1182\/hematology.2020000123","article-title":"A patient with Gaucher disease and plasma cell dyscrasia: bidirectional impact","author":"Zimran","year":"2020","journal-title":"Hematol. Am. Soc. Hematol. Educ.Progr."}],"container-title":["Neurochemistry International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018624001013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018624001013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T19:27:46Z","timestamp":1722454066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197018624001013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":88,"alternative-id":["S0197018624001013"],"URL":"https:\/\/doi.org\/10.1016\/j.neuint.2024.105774","relation":{},"ISSN":["0197-0186"],"issn-type":[{"value":"0197-0186","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular mechanisms of the ambroxol action in Gaucher disease and GBA1 mutation-associated Parkinson disease","name":"articletitle","label":"Article Title"},{"value":"Neurochemistry International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuint.2024.105774","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105774"}}